OPGx-BEST1 Shows Early Signals in Five Treated Participants

Evidence Company disclosure · Discovery September 9, 2026 · Importance 4/5 · Direction Uncertain Summary Opus Genetics reported low-dose Cohort 1 results from the open-label Phase I/II BIRD-1 study of subretinal OPGx-BEST1 in five adults with BEST1-related retinal disease. All five improved on at least…